SCHEMBL19626732

SCHEMBL19626732

Cc1nc(-c2cccc(N(C)C)c2)cs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 3/20 0.62
TSHR P16473 1/20 0.62
PRMT6 Q96LA8 1/20 0.55
HTT P42858 2/20 0.52
GFER P55789 2/20 0.52
MAPT P10636 4/20 0.51
ALDH1A1 P00352 3/20 0.51
HPGD P15428 2/20 0.51
GAA P10253 2/20 0.51
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51
ESR2 Q92731 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
ROCK2 O75116 1/20 0.49
PIM1 P11309 1/20 0.49
GSK3B P49841 1/20 0.49
AURKB Q96GD4 1/20 0.49
SCN9A Q15858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26246346 0.84 ALDH1A1 (0.59) RECQLTSHRHTTGFERMAPT
SCHEMBL30030077 0.84 ALDH1A1 (0.59) RECQLTSHRHTTGFERMAPT
SCHEMBL19625383 0.83 SMN1; SMN2 (0.46) RECQLTSHRPRMT6HTTGFER
SCHEMBL19627010 0.83 GFER (0.59) RECQLTSHRPRMT6HTTGFER
SCHEMBL8257849 0.80 RECQL (0.70) RECQLTSHRPRMT6HTTGFER
SCHEMBL19626485 0.80 GAA (0.57) RECQLTSHRHTTMAPTALDH1A1
SCHEMBL2739994 0.79 MAPT (0.63) HTTMAPTALDH1A1GAAKDM4E
SCHEMBL4320174 0.79 LMNA (0.53) RECQLTSHRPRMT6HTTGFER
SCHEMBL10076588 0.78 RECQL (0.68) RECQLTSHRPRMT6HTTGFER
SCHEMBL26967664 0.78 SMN1; SMN2 (0.53) TSHRMAPTALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286973-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2023-09-14 US disclosed
US-20170334912-A1 Purine Diones As Wnt Pathway Modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334912-A1 Purine Diones As Wnt Pathway Modulators WNT1, WNT3A, CTNNB1 RECQL 1370/4885TSHR 1830/4885PRMT6 1600/4885
US-20230286973-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G RECQL 1059/4885TSHR 2746/4885PRMT6 2754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.